Peer Reviewed
Perspectives

New percutaneous treatments for aortic and mitral valve disease

Mathivathana Indrajith, Mehrdad Emami, Sushil Allen Luis, Karl Poon, Darren L Walters
Abstract
Percutaneous treatments for aortic and mitral valve disease have made significant progress over the past decade. They are currently best used in those patients who are high risk or unsuitable for conventional surgical valve repair or replacements. Further studies are needed before these treatments can be recommended in lower-risk patients.
Key Points
  • New treatments for valvular heart disease target older patients at high surgical risk.
  • Transcatheter aortic valve replacement may be indicated for selected patients with symptomatic severe aortic valve stenosis.
  • Percutaneous mitral valve repair may be considered for selected patients with symptomatic severe mitral regurgitation.
  • Surgery continues to be the standard therapy for most patients with these conditions.
  • Ongoing clinical trials will determine the role of these novel treatments in the future.
Purchase the PDF version of this article
Already a subscriber?